Table 3.
Cohort 1 | Cohort 2 | Total | |||
---|---|---|---|---|---|
Rising PSA | Metastatic | Rising PSA | Metastatic | ||
Treatment-specific undetectable PSA outcome | |||||
No. evaluable | 25 | 37 | 17 | 21 | 100 |
6 monthsa, No. (%) | 9 (36%) | 14 (38%) | 13 (76%) | 12 (57%) | 48 (48%) |
18 months, No. (%) | 0 | 0 | 3 (18%) | 2 (10%) | 5b (5%) |
Time to progression | |||||
---|---|---|---|---|---|
Rising PSA | Metastatic | Rising PSA | Metastatic | Total | |
No. evaluable | 25 | 37 | 14 | 19 | 95c |
Median, months | 9 | 10 | 14 | 13 | 13 |
Range, months | 8–15 | 8–14 | 11–19 | 6–21 | 8–21 |
6 28-day docetaxel cycles for cohort 1 and 9 21-day docetaxel cycles for cohort 2.
All 5 patients achieved an undetectable PSA by cycle 6.
5 patients in cohort 2 remain on study at a median of 23+ months (range 18+ to 26+)